The lack of changes in measured CYP450 activities in hyperglycemic MPCCs are not always consistent with changes in CYP450 activities observed in patients with NAFLD, such as decreased CYP3A4/3A5 activity34, 35, 36, decreased CYP1A2 activity35, 37, 38 and increased CYP2A6 activity38. The gene discussed is CYP1A2; the disease is metabolic dysfunction-associated steatotic liver disease.